Athira Pharma, Inc. | Business Contracts

Change in Control and Severance Agreement between the Registrant and Kevin Church (Filed With SEC on March 28, 2022)

Offer Letter between the Registrant and Mark Worthington (Filed With SEC on August 16, 2021)

Description of Capital Stock (Filed With SEC on March 25, 2021)

Form of Director and Executive Officer Indemnification Agreement (Filed With SEC on August 26, 2020)

Amendment to Employment Agreement between the Registrant and Hans Moebius, Ph.D (Filed With SEC on March 28, 2022)

Outside Director Compensation Policy, as amended (Filed With SEC on January 31, 2022)

Separation Agreement dated October 18, 2021 between Leen Kawas and Athira (Filed With SEC on October 21, 2021)

Change in Control and Severance Agreement between the Registrant and Rachel Lenington (Filed With SEC on August 16, 2021)

Offer Letter between the Registrant and Rachel Lenington (Filed With SEC on August 16, 2021)

Change in Control and Severance Agreement between the Registrant and Mark Worthington (Filed With SEC on August 16, 2021)

Form of Underwriting Agreement (Filed With SEC on January 19, 2021)

Change in Control and Severance Agreement between the Registrant and Hans Moebius, Ph.D (Filed With SEC on September 14, 2020)

Employment Offer Letter between the Registrant and Hans Moebius, Ph.D (Filed With SEC on September 14, 2020)

Specimen Common Stock Certificate of the Registrant (Filed With SEC on September 14, 2020)

Confirmatory Employment Letter between the Registrant and Kevin Church, Ph.D (Filed With SEC on September 9, 2020)

Change in Control and Severance Agreement between the Registrant and Glenna Mileson (Filed With SEC on September 9, 2020)

Change in Control and Severance Agreement between the Registrant and Mark Litton, Ph.D (Filed With SEC on September 9, 2020)

Change in Control and Severance Agreement between the Registrant and Leen Kawas, Ph.D (Filed With SEC on September 9, 2020)

Confirmatory Employment Letter between the Registrant and Glenna Mileson (Filed With SEC on September 9, 2020)

Confirmatory Employment Letter between the Registrant and Mark Litton, Ph.D (Filed With SEC on September 9, 2020)

Form of Restricted Share Award under the 2014 Equity Incentive Plan (Filed With SEC on September 9, 2020)

2020 Equity Incentive Plan (Filed With SEC on September 9, 2020)

Warrant to Purchase Common Stock of the Registrant, dated April 8, 2013 (Filed With SEC on September 9, 2020)

Warrant to Purchase Common Stock of the Registrant, dated August 26, 2020 (Filed With SEC on September 9, 2020)

2014 Equity Incentive Plan, as amended (Filed With SEC on September 9, 2020)

Form of Stock Option Agreement under the 2014 Equity Incentive Plan (Filed With SEC on September 9, 2020)

Confirmatory Employment Letter between the Registrant and Leen Kawas, Ph.D (Filed With SEC on September 9, 2020)

Form of Stock Option Agreement under the 2020 Equity Incentive Plan (Filed With SEC on September 9, 2020)

Form of Restricted Stock Award Agreement under the 2020 Equity Incentive Plan (Filed With SEC on September 9, 2020)

Form of RSU Agreement under the 2020 Equity Incentive Plan (Filed With SEC on September 9, 2020)

2020 Employee Stock Purchase Plan and Form of Subscription Agreement thereunder (Filed With SEC on September 9, 2020)

Outside Director Compensation Policy (Filed With SEC on September 9, 2020)

Executive Incentive Compensation Plan (Filed With SEC on September 9, 2020)

Form of Underwriting Agreement (Filed With SEC on September 9, 2020)

Form of Warrant to Purchase Common Stock (Filed With SEC on August 26, 2020)

Form of Warrant to Purchase Series B Preferred Stock (Filed With SEC on August 26, 2020)

Athira Pharma, Inc. (41)